Key Statistics for Bladder Cancer. 2022. Updated 1/12/2022. https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Accessed 13 July 2022.

Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Bladder cancer. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed 18 June 2022.

Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24(10):730–4. https://doi.org/10.1111/iju.13376.

Article  PubMed  Google Scholar 

Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788.

Article  CAS  PubMed  Google Scholar 

Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. https://doi.org/10.1056/NEJMoa1613683.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22. https://doi.org/10.1016/S1470-2045(17)30065-7.

Article  CAS  PubMed  Google Scholar 

Apolo AB, Ellerton JA, Infante JR, et al. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN solid tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020;8(2):e001246. https://doi.org/10.1136/jitc-2020-001246.

Article  PubMed  PubMed Central  Google Scholar 

Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8. https://doi.org/10.1038/nature12213.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–56. https://doi.org/10.1016/j.cell.2017.09.007. (e25).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Ahmadie H, Netto GJ. Molecular pathology of urothelial carcinoma. Surg Pathol Clin. 2021;14(3):403–14. https://doi.org/10.1016/j.path.2021.05.005.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Han X, Li L, et al. Role of Nectin4 protein in cancer (Review). Int J Oncol. 2021. https://doi.org/10.3892/ijo.2021.5273.

Article  PubMed  PubMed Central  Google Scholar 

Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021;18(2):93–103. https://doi.org/10.1038/s41585-020-00394-5.

Article  PubMed  Google Scholar 

Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol. 2019;31(3):207–15. https://doi.org/10.1097/CCO.0000000000000532.

Article  PubMed  Google Scholar 

Tomiyama E, Fujita K, Rodriguez Pena MDC, et al. Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21155390.

Article  PubMed  PubMed Central  Google Scholar 

Rosenberg J, Sridhar SS, Zhang J, et al. EV-101: a phase i study of single-agent enfortumab vedotin in patients with Nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38(10):1041–9. https://doi.org/10.1200/jco.19.02044.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9(48):28989–9006. https://doi.org/10.18632/oncotarget.25615.

Article  PubMed  PubMed Central  Google Scholar 

Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222–33. https://doi.org/10.1038/onc.2012.36.

Article  CAS  PubMed  Google Scholar 

Wang J, Zhang K, Grabowska D, et al. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol Cancer Res. 2011;9(12):1686–95. https://doi.org/10.1158/1541-7786.MCR-11-0241.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Avellini C, Licini C, Lazzarini R, et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget. 2017;8(35):58642–53. https://doi.org/10.18632/oncotarget.17407.

Article  PubMed  PubMed Central  Google Scholar 

Klute K, Nackos E, Tasaki S, Nguyen DP, Bander NH, Tagawa ST. Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Oncotargets Ther. 2014;7:2227–36. https://doi.org/10.2147/OTT.S46887.

Article  Google Scholar 

Vlachostergios PJ, Jakubowski CD, Niaz MJ, et al. Antibody-drug conjugates in bladder cancer. Bladder Cancer. 2018;4(3):247–59. https://doi.org/10.3233/BLC-180169.

Article  PubMed  PubMed Central  Google Scholar 

Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Target Oncol. 2017;12(6):719–39. https://doi.org/10.1007/s11523-017-0535-0.

Article  PubMed  Google Scholar 

Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54. https://doi.org/10.1200/JCO.2001.19.13.3244.

Article  CAS  PubMed  Google Scholar 

Kim, J. H., & Chang, I. H. (2022). A novel strategy for treatment of bladder cancer: Antibody-drug conjugates. Investigative and clinical urology, 63(4), 373–384. https://doi.org/10.4111/icu.20220061

Article  PubMed  PubMed Central  Google Scholar 

Lattanzi M, Rosenberg JE. The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Rev Anticancer Ther. 2020;20(7):551–61. https://doi.org/10.1080/14737140.2020.1782201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody–drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3–19. https://doi.org/10.1158/1541-7786.Mcr-19-0582.

Article  CAS  PubMed  Google Scholar 

Abel M, Burkenroad A, Sun A, Lu E, Stefanoudakis D, Drakaki A. The evolving landscape of antibody-drug conjugates for urothelial carcinoma. Clin Genitourin Cancer. 2021;19(3):183–93. https://doi.org/10.1016/j.clgc.2020.11.006.

Article  PubMed  Google Scholar 

Lambert JM, Morris CQ. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34(5):1015–35. https://doi.org/10.1007/s12325-017-0519-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–600. https://doi.org/10.1200/jco.19.01140.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–35. https://doi.org/10.1056/NEJMoa2035807.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872–82. https://doi.org/10.1016/S1470-2045(21)00094-2.

Article  CAS  PubMed  Google Scholar 

Moussa M, Papatsoris A, Abou Chakra M, Dellis A. Profile of enfortumab vedotin in the treatment of urothelial carcinoma: the evidence to date. Drug Des Dev Ther. 2021;15:453–62. https://doi.org/10.2147/DDDT.S240854.

Article  Google Scholar 

Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol. 2016;102:1–6. https://doi.org/10.1016/j.bcp.2015.12.008.

Article  CAS  PubMed  Google Scholar 

Muller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2(8):741–55. https://doi.org/10.1158/2326-6066.CIR-13-0198.

Article  CAS  PubMed  Google Scholar 

Müller P, Kreuzaler M, Khan T, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med. 2015;7(315):315ra188. https://doi.org/10.1126/scitranslmed.aac4925.

Article  CAS  PubMed  Google Scholar 

Heijden MSVD, Gupta S, Galsky MD, et al. Study EV-302: a two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress). J Clin Oncol. 2022;40(6_suppl):TPS589. https://doi.org/10.1200/JCO.2022.40.6_suppl.TPS589.

Article  Google Scholar 

Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023. https://doi.org/10.1200/jco.22.01643.

Article  PubMed